Cowen reiterated their buy rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on Wednesday. Cowen currently has a $22.00 price target on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. Leerink Swann reiterated a buy rating and set a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Bank of America raised their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a buy rating in a report on Wednesday, October 4th. Chardan Capital restated a buy rating and issued a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a hold rating to a buy rating and set a $16.00 target price for the company in a report on Tuesday, October 10th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $18.31.
Amicus Therapeutics (FOLD) opened at $15.72 on Wednesday. Amicus Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The company has a market cap of $2,610.00, a price-to-earnings ratio of -8.59 and a beta of 1.72.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter last year, the business earned ($0.33) EPS. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year. equities research analysts forecast that Amicus Therapeutics will post -1.56 EPS for the current fiscal year.
In related news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the completion of the sale, the insider now owns 69,184 shares in the company, valued at approximately $1,017,696.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Daphne Quimi sold 8,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the sale, the senior vice president now owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders sold a total of 718,920 shares of company stock valued at $10,263,669 in the last 90 days. Company insiders own 3.40% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio bought a new stake in Amicus Therapeutics during the 3rd quarter valued at about $102,000. Birchview Capital LP bought a new stake in Amicus Therapeutics during the 3rd quarter valued at about $151,000. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics during the 3rd quarter valued at about $154,000. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the 3rd quarter valued at about $155,000. Finally, Tudor Investment Corp ET AL bought a new stake in Amicus Therapeutics during the 2nd quarter valued at about $124,000.
ILLEGAL ACTIVITY NOTICE: “Cowen Reaffirms Buy Rating for Amicus Therapeutics (FOLD)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/cowen-reaffirms-buy-rating-for-amicus-therapeutics-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.